

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Top Eminent Healthcare Group Limited

(卓著健康集團有限公司)*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6877)

INSIDE INFORMATION LITIGATION UPDATE

This announcement is made by Top Eminent Healthcare Group Limited (the “**Company**”), together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the litigation involving, among others, the Company and Banclogix System Co., Limited (“**Banclogix**”) under High Court Action Nos. 1416 of 2019 and 452 of 2020 in the Court of First Instance of the High Court of Hong Kong, and the Company’s announcements dated 6 August 2019 and 12 May 2020 in relation thereto, including the injunction proceedings and the subsequent litigation between the parties.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that judgment in the above proceedings was handed down by the Court of First Instance of the High Court of Hong Kong on 22 May 2026.

THE JUDGMENT

Pursuant to the judgment:

- the claims advanced by the Company and the other plaintiffs in HCA 1416/2019 were dismissed;
- in HCA 452/2020, the Company was ordered to pay Banclogix the following sums: (i) a termination fee of HK\$2,500,000; and (ii) a software fee of HK\$448,560, together with interest;
- Banclogix’s claim for an IT fee in the sum of HK\$1,500,000 was dismissed; and
- the Court made an order *nisi* as to costs against the Company, subject to further directions or determination by the Court.

The Company is currently reviewing the outcome of the judgment and seeking legal advice with its legal advisers to consider the appropriate course of action, including the possibility of lodging an appeal.

IMPACT ON THE GROUP

Based on the Board's preliminary assessment and information currently available, the financial impact arising from the judgment would primarily relate to (i) the amounts payable under the judgment, (ii) the related interest, and (iii) the costs of the proceedings, including the costs order *nisi* made by the Court, the amount of which has yet to be assessed or agreed between the parties.

The Group will assess, on an ongoing basis, the accounting treatment of the judgment and the related costs in accordance with the applicable accounting standards.

The Board wishes to emphasise that the Group's overall business operations remain normal. Further announcement(s) will be made by the Company as and when appropriate in accordance with the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Top Eminent Healthcare Group Limited
Ji Guangfei
Chairman

Hong Kong, 22 May 2026

As at the date of this announcement, the Board comprises three Executive Directors, namely Mr. Ji Guangfei (Chairman and Chief Executive Officer), Ms. Li Jiang (Deputy Chairman) and Mr. Zhang Huanping; three Non-Executive Directors, namely Mr. Li Jiong, Mr. Yuan Feng and Mr. Chung Cheuk Fan Marco; and three Independent Non-Executive Directors, namely Mr. Zhou Jiannan (Lead INED), Ms. Hu Zhaoxia and Mr. Lyu Aiping.

* *For identification purpose only*